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Objectives. Information on the efficacy of GH treatment in short SGA children starting their treatment in adolescence is limited.
Therefore, adult height (AH), total height gain, and pubertal height gain were evaluated in short SGA children who started GH
treatment at pubertal onset. Patient and Methods. Growth data of 47 short SGA adolescents (22 boys) who started GH
treatment at pubertal onset (PUB group) were compared with results from 27 short SGA patients (11 boys) who started GH
therapy at least 1 year before pubertal onset (PrePUB group). Results. The PUB group achieved a mean (±SD) total height gain
of 0.8± 0.7 SDS and an AH of −2.5± 0.7 SDS after 4.1± 1.1 years of GH treatment with a dosage of 41.8± 8.4 μg/kg/day. These
results were comparable with those in the PrePUB group, which was treated for a longer duration (5.8± 2.1 years), resulting in a
total height gain of 1.1± 0.7 SDS and an AH of −2.1± 1.0 SDS. Multiple regression analysis showed a significantly lower height
gain in pubertal patients, females, and patients weighing less at start of GH treatment. An AH above −2 SDS and above the
parent-specific lower limit of height was, respectively, reached in 28% and 70% of PUB and 44% and 67% of PrePUB patients
(NS). AH SDS was positively correlated with the height SDS at start of GH. Conclusions. Short SGA adolescents starting GH
therapy at an early pubertal stage have a modest and variable height gain. A normal AH can be expected in one third of the
patients, especially in those with a smaller height deficit at onset of GH treatment.
1. Introduction
In Europe, growth hormone (GH) treatment is, since 2003,
an approved growth-promoting therapy for children born
small for gestational age (SGA) who do not show postnatal
spontaneous catch-up growth. In Belgium, GH treatment is
reimbursed since 2004 for short (<−2.5 SDS) SGA children,
aged 4 years or older with a height> 1 SDS below midparen-
tal height and without catch-up growth (height velocity
(HV)< 0.0 SDS). Adult height (AH) in short SGA children
treated with GH is mainly dependent on the duration of
treatment: the best response is obtained when treatment is
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started several years before the onset of puberty [1, 2]. Early
diagnosis and referral for treatment of SGA children without
catch-up growth before puberty has therefore been advocated
[3].
Currently, median age at start of GH treatment in short
SGA children in Belgium is 7.7 years (data on file, Belgian
Society for Pediatric Endocrinology and Diabetology
(BESPEED)). Despite efforts to promote early referral of
short SGA children during the last decennium in most Euro-
pean countries, a variable percentage of short SGA children
still consults for growth-promoting therapy around the onset
of puberty (up to 17% in Belgium). Upper limits for chrono-
logical age or bone age for efficacious initiation of GH ther-
apy have not been studied. Increasing the dose of GH and/
or additional treatment with GnRH agonists remain contro-
versial issues in the management of short SGA adolescents,
presenting with a major height deficit, and are not commonly
performed in Belgium [4, 5].
To determine whether it is justified to start a GH treat-
ment at early pubertal onset in short SGA adolescents, we
retrospectively analysed our national GH registry. Pubertal
height gain and AH were analysed in children who started
GH around the onset of puberty and compared with the out-
comes in short SGA children who initiated GH therapy at
least one year before the onset of puberty. Efficacy of the
treatment was measured by the following parameters: mean
total height gain (in SDS), mean AH SDS and percentage of
patients reaching an adult height>−2 SDS (167.6 cm for boys
and 154.7 cm for girls in Belgium), and mean AH SDS cor-
rected for midparental height and percentage of patients
reaching an AH above the parent-specific lower limit of
height.
2. Patients and Methods
2.1. Patients. Growth data of GH-treated short SGA chil-
dren were retrieved from the Belgian registry of GH-
treated children (BELGROW). This registry collects coded
data since 1985 and was approved by the Ethical Com-
mittees of the participating centres of the BESPEED
members. Informed consent was secured prior to entry
of data in the registry.
Inclusion criteria were as follows: (1) diagnosis of SGA
(Birth weight and/or length<−2 SDS), (2) treatment with
recombinant human GH (rGH), given continuously on a
daily basis during at least 3 years when treatment started
before puberty and at least 2 years when started near the
onset of puberty, (3) breast stage <B3 for girls and a testicular
volume< 10ml for boys at the start of GH therapy, and (4)
achievement of AH, defined as a height velocity< 2 cm/year.
Exclusion criteria were as follows: (1) patients with a known
syndrome (including Silver-Russell syndrome) and/or
having major malformations and (2) treatment with GnRH
agonist or other GH-promoting agents, such as oxandrolone
or letrozole.
In total, 196 short SGA patients treated since 1988 with a
daily regimen of rGH, no documented syndrome or major
malformations, aged more than 16 years (girls) and 18 years
(boys) by the end of 2012, and who stopped GH therapy were
retrieved from BELGROW (Figure 1). Ten patients treated
with GnRH agonists were excluded, and data of 34 patients
were not analysed because of intermittent GH treatment.
Out of the 152 remaining patients, 35 had a too advanced
pubertal development to be included. Twenty additional
patients were excluded because the treatment duration
was less than 3 years when prepubertal at the start of
treatment or less than 2 years when pubertal at the start
of treatment. For 74 (76%) of the 97 remaining patients,
an AH (HV< 2 cm/year) was documented in the registry
(n = 61) or obtained from the family doctor (n = 13). Birth
and auxological characteristics at onset of GH treatment
were comparable in patients with and without data on
AH (data not shown).
The 74 included patients were divided into 2 groups
according to their degree of pubertal maturation at start of
GH treatment and/or during the first year of GH therapy:
27 patients (11 boys) started GH at least 1 year before the
onset of puberty (PrePUB group) and 47 patients (22 boys)
either started GH when they were already in puberty (at an








Aged > 16 yrs (girls), >18 yrs (boys)
Treated with rGH on a daily regimen
GH therapy stopped
10 GnRH agonist treatment
34 with intermittent GH treatment
35 with too advanced pubertal development
20 with GH treatment duration < 3yrs (in PreBUB group)
or 2 yrs (in PUB group)
23 lacked adult height
Figure 1: Patients selection flowchart.
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early stage) (n = 28) or entered in puberty during the first
year of treatment (n = 19) (PUB group).
2.2. Methods. At baseline and during follow-up visits every 3
to 6 months, the following data were collected: chronological
age, height, body weight, pubertal stage, dose of GH, and
adverse events. Pubertal staging was determined according
to Tanner and Whitehouse [6].
Anthropometric data (height, weight, and BMI) were
expressed as z-scores adjusted for age and gender using the
Flemish population references [7]. AH was defined as a
height reached when growth velocity was <2 cm/year. AH
SDS was calculated using adult references (SDS for age 21
years). Birth weight and length were expressed as z-scores
adjusted for gestational age using the reference of Niklasson
et al. [8]. The midparental height (MPH) SDS was calculated
as (father’s height SDS+mother’s height SDS)/1.61 [9]. First
year height velocity and gain in height SDS were calculated if
measurements were available between 9 and 15 months after
the start of GH therapy. Onset of puberty was defined by a
testicular volume≥ 4ml in boys and the presence of a breast
stage 2 (B2) in girls. Pubertal height gain (cm or SDS),
defined by the AH (cm or SDS) minus the height at onset
of puberty (cm or SDS), was calculated if a visit was available
with pubertal development B2 in girls and testis volume 4ml
in boys (n = 68). Total height gain was calculated as AH
minus height at start of GH. The parent-specific lower limit
of height SDS range was calculated as (0.5×midparental
height SDS)− 1.73 SDS [9]. Mean daily dosage (μg/kg/day)
during the whole treatment period was calculated using the
dosage recorded at each visit.
2.3. Statistical Analysis. Results are expressed as mean± SD.
Both the percentage of subjects with an AH SDS>−2
and an AH SDS above the parent-specific lower limit
was calculated. Continuous variables and percentages
were compared across groups using unpaired t-tests,
Mann–Whitney U tests, or chi-square tests as appropri-
ate. Multiple regression analysis with backward stepwise
variable selection was used to analyse the relationship
between characteristics of the patients and treatment param-
eters as independent variables and adult height SDS or total
height gain SDS as the outcome. A p value < 0.05 was consid-
ered statistically significant. Stata 10.1 and IBM SPSS
Statistics 21® were used for the statistical analysis.
3. Results
3.1. Auxological Characteristics (Table 1). Birth and parental
auxological data were comparable in the PrePUB and
PUB groups, as shown in Table 1. MPH SDS was in both
groups significantly (p < 0 001) lower compared to the
general population.
3.2. Growth Response, Adult Height, and Total Height Gain
SDS (Table 2). At onset and at the end of GH treatment,
height SDS was comparable in the PrePUB and PUB groups.
The total height gain SDS (1.1± 0.7 in the PrePUB versus 0.8
± 0.7 in the PUB group) was also similar after, respectively,
5.8± 2.1 and 4.1± 1.1 years of GH treatment (p < 0 001).
There was no significant difference in duration of GH treat-
ment between males and females in the PUB group, but
males in the PrePUB group were treated longer (6.8± 2.5 ver-
sus 5.1± 1.3 years (p = 0 03)). A total height gain> 0.5 SDS
was observed in 85% (23/27) of patients in the PrePUB group
and in 64% (30/47) of patients in the PUB group (p = 0 06)
(Figures 2(a) and 2(b)). Absolute AH was, respectively,
167.5± 7.7 in boys and 153.4± 4.8 cm in girls in the PrePUB
group and, respectively, 165.2± 4.9 and 150.8± 4.4 cm in the
PUB group. Whereas AH was above −2 SDS in 44.4% of the
PrePUB group and in 27.7% of the PUB group (p = NS),
respectively, 66.7% and 69.8% reached an AH above their
parent-specific lower limit (p = NS).
3.3. Pubertal Growth (Table 3).Height SDS at start of puberty
was significantly lower in the PUB group compared to the
PrePUB group. In the PUB group, there was a gain of 0.6
± 0.7 in height SDS from onset of puberty until AH, while
in the PrePUB group, height SDS increased by 0.2± 0.9 dur-
ing this period. Total pubertal height gain in boys as well as
girls was significantly higher in the PUB group than the Pre-
PUB patients (resp., 28.2± 5.3 versus 23.2± 3.3 cm in boys
and 21.5± 5.6 versus 16.7± 5.3 cm in girls).
3.4. Multivariate Analysis (Table 4). Multiple linear regres-
sion was used to determine the factors influencing the AH
SDS and the total height gain. The following variables were
included in the model: birth length and weight SDS, gender,
target height SDS, height and weight SDS at start, mean total
dosage (μg/kg/day), total duration of GH therapy, height
gain SDS during the first year of GH therapy, and the group
factor PrePUB or PUB. A significantly lower growth response
and adult height outcome was observed in females in
Table 1: Comparison of birth and parental auxological data between the PrePUB and PUB groups.
n PrePUB group (n = 27) PUB group (n = 47) Significance
Boys/girls, n 74 11/16 22/25 p = 0 61
Birth weight, SDS 73 −2.5± 1.0 −2.5± 0.8 p = 0 78
Birth length, SDS 71 −3.0± 0.9 −2.6± 0.8 p = 0 12
Father’s height, SDS 67 −1.3± 1.1 −1.7± 1.0 p = 0 14
Mother’s height, SDS 67 −1.2± 1.1 −1.5± 1.2 p = 0 35
Midparental height, SDS 67 −1.6± 1.0 −1.9± 0.9 p = 0 10
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comparison with males, in patients lighter at start of GH
treatment and in pubertal patients. AH SDS was positively
correlated with the height SDS at start of GH.
4. Discussion
Our retrospective study showed that short SGA adolescents
starting GH treatment just before (less than one year) the
onset of puberty or at an early pubertal stage (around a mean
age of 12.3 years) have a modest and variable height gain (0.8
± 0.7 SDS) when treated for 4 years at a mean dosage of
42μg/kg/day. Only one third of them obtained a normal
AH, which was positively associated with height at start.
On the other hand, GH-treated SGA adolescents reached
an AH within parental target height range in a similar per-
centage as SGA children who were treated at least 1 year
before the onset of puberty with a similar dosage but for lon-
ger duration (1.7 years longer). In addition, their pubertal
height gain was greater than that of the prepubertal children
starting GH treatment 2.3 years earlier. Our data suggest that
when short SGA adolescents are requesting GH therapy and
are responding to the reimbursement criteria, they should
not be excluded from GH treatment because of their older
age and imminent pubertal development, but a realistic
growth prognosis should always be given.
The observed pubertal height gain in the SGA subjects
starting GH treatment around puberty in our study was com-
parable with that observed in healthy British children, which
is 29.5 cm in boys (testis volume> 3ml) and 19.2 cm in girls
(Tanner stage B2) [10]. In a Spanish study, 31 untreated short
SGAchildren had a smaller pubertal height gain than reported






















Figure 2: Scatterplot of total height gain SDS in relation to adult height SDS in the PrePUB group (a) and the PUB group (b).
Table 3: Comparison of auxological data at onset of puberty and during puberty between the PrePUB and PUB groups.
n PrePUB group PUB group
Significance
n Males (n = 11) Females (n = 16) n Males (n = 22) Females (n = 25)
Height gain from start of GH until
pubertal onset
Delta height, SDS 53 26 0.9± 0.6 27∗∗ 0.2± 0.2 p < 0 001
Data at start of puberty
Age (yr) 68 26 13.4± 1.3 12.1± 2.0 42 13.4± 1.1 11.6± 1.2 p = 0 98/p = 0 25∗
Height, SDS 68 26 −2.3± 0.6 42 −3.1± 0.7 p < 0 001
Weight, SDS 68 26 −2.2± 1.0 42 −2.7± 1.1 p = 0 04
BMI, SDS 68 26 −1.0± 0.9 42 −1.2± 1.2 p = 0 68
Height gain from onset of puberty
until AH
Delta height, SDS 68 26 0.2± 0.9 42 0.6± 0.7 p = 0 056
Delta height (cm) 68 26 23.2± 3.3 16.7± 5.3 42 28.2± 5.3 21.5± 5.6 p = 0 01/p = 0 01∗
∗In males from the PrePUB group versus the PUB group/in females from the PrePUB group versus the PUB group. ∗∗In the PUB group, height gain from start
of GH until pubertal onset was calculated only if GH therapy was started before or at onset of puberty.
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similar total pubertal growth and peak height velocity was
observed in short SGA children (n = 76) in comparison with
short children born appropriate for gestational age (n = 52).
However, the earlier onset of puberty in SGA children was
not taken into account in this particular study [12].
In our study, age at start of puberty was relatively late, in
both boys and girls. We suspect that besides the exclusion of
patients with additional GnRH treatment, a recruitment bias
might be involved, as mainly short adolescents with a later
onset of puberty, experiencing a more pronounced prepuber-
tal growth deceleration, might have requested GH treatment.
Without GH treatment, a rather low pubertal gain had to be
expected. The GH treatment allowed the short SGA patients
to present with a normal pubertal height gain as in normal
growing non-SGA adolescents. In the prepubertal group,
the observed pubertal height gain was comparable with the
increments reported by Ranke and Lindberg in a group of
59 (24 females) short SGA children treated at least two years
before puberty onset [13].
Studies evaluating adult height of short SGA children
starting GH around pubertal onset are scarce. Carel et al.
[14] treated with GH a cohort of 91 early pubertal SGA chil-
dren at a mean age of 12.6 years for a relative short duration
of 2.7± 0.6 years, at a relatively high dosage of 67μg/kg/day.
Many participants discontinued their treatment prematurely,
before their height velocity was <2 cm/year. Total height gain
was 1.1± 0.9 SDS, making it possible for 47% of the treated
SGA adolescents to achieve an adult height within the nor-
mal range for the general population (>−2 SDS). Lem et al.
[5] confirmed that SGA patients starting GH treatment dur-
ing adolescence at a median age of 11.2 years (when 46%
were already in puberty) at a dosage of either 33 or 66μg/
kg/day still can have a significant catch-up growth. In 84
patients who attained AH, height improved from −2.9
SDS at start of treatment to −1.7 SDS at AH (height gain
around 1.2 SDS), permitting 62% of adolescents to attain
an adult height above −2 SDS.
In our study, the almost similar growth outcome of
SGA children treated around puberty with those starting
some years before puberty might be partly explained by
the relatively short duration of GH treatment in the pre-
pubertal group, who started GH therapy at a relatively
advanced age of 10.0 years. Studies reporting on the adult
height and total height gain in prepubertal short SGA chil-
dren after continuous GH therapy, but starting GH treat-
ment at a much younger mean age than our cohort, have
found better growth outcomes. Mean height gain was 1.4
SDS (n = 162; GH start around 7.8 yr) in the study of Ranke
and Lindberg [2] and 1.7 SDS (n = 73; GH start at 7.7 yr) in
the study of Bannink et al. [1]. We expect that within the fol-
lowing 5 years, more SGA patients who have started GH at a
younger age will attain adult height and be available in our
registry for a comparative adult height analysis. In addition,
the study of quality of life outcome and employment status
in relation to the age at start of treatment might be of interest
in this cohort of SGA patients.
Given the wide variation in GH-induced growth
response in both prepubertal and pubertal subjects, predic-
tors of the growth response and AH were evaluated. Like in
other studies [2, 15, 16], AH was found to be positively
related to the height SDS at start. In accordance with the
findings of Dahlgren and Wikland [15] including prepuber-
tal short SGA children, lighter SGA adolescents were found
to experience better height gain in our study. We hypothe-
size that a lower adiposity at start of GH therapy in SGA
children and especially in adolescents might induce a lesser
degree of adrenal hyperandrogenism and/or compensatory
hyperinsulinemia causing less bone age acceleration [17,
18]. In addition, the growth response and final height out-
come to GH in our study was found to be gender depen-
dent. The lower growth response in girls compared to
boys in the PUB group was not explained by a difference
in treatment duration, but may be related to the stronger
influence of estrogens than androgens on bone maturation.
Decreased as well as increased serum estradiol levels have
been found in SGA children at completion of puberty
[19]. Furthermore, SGA females, in comparison with males,
might be at risk for a more pronounced adrenarche and/or
insulin resistance, which are both associated with a more
rapid bone maturation [20–22]. In our study, no effect of
the GH dosage on AH outcome was found, but the dosage
administered ranged only between 32 and 53μg/kg/day for
90% of the population. Whereas in the prepubertal years a
dose-dependent height gain has been found in most stud-
ies, this might be of less importance on the long term
and in pubertal SGA children [15, 23–25].
Our study has several limitations. It was a retrospective
study, without a control group on a relatively small number
of patients. In retrospective studies and studies in whom a
great proportion are lost to follow-up (for a quarter of the
patients, no adult height was reported in our registry), some
overestimation of the effect might be present. However, non-
registry studies have reported similar or even better growth
effects in SGA adolescents [5, 14]. On the other hand, our
approach to calculate AH SDS using adult references (SDS
for age 21 years) may underestimate the AH SDS as some
patients could have grown a few centimetres after the last
visit available in the registry. The registry does not include
untreated SGA children, making a direct comparison with
untreated patients not possible. In untreated short SGA ado-
lescents, a 0.5 SDS height increase from onset of puberty has
been reported previously by Carel et al. [14] and should be
Table 4: Results of multiple linear regression analysis with adult






R p R p
Intercept 0.97 1.46
Gender (female) −0.33 0.042 −0.34 0.04
Height SDS at start 0.89 <0.001 —
Weight SDS at start −0.18 0.040 −0.21 0.006
Mean GH dosage (μg/kg/day) −0.02 0.081 −0.02 0.06
Group (pubertal) −0.35 0.042 −0.33 0.05
R2 0.43 0.21
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taken into account. Retrieval of historical controls for
comparison was judged difficult from the participating cen-
tres, since longitudinal data up to adult height are needed
and the secular trend might favour a higher AH in the
current GH-treated group.
To increase the efficacy of GH treatment in short SGA
adolescents, several options have been tried or are still under
investigation. Higher GH dosages have been studied in a
recent trial by Lem et al. [5]. These authors showed that
SGA patients starting their treatment around puberty and
treated with a GH dosage of 66μg/kg/day obtained a 0.5-
0.6 SDS higher AH compared to those treated at 33μg/kg/
day, after correcting for influencing variables (gender, age
at start, height SDS at start, treatment years before puberty,
and target height SDS). However, the decision of treating
SGA patients with higher GH doses must be weighed against
potential long-term safety issues, given the risk of elevated
serum IGF-1 levels in up to one third of the patients when
GH dosages of 66μg/kg/day are given [26]. Furthermore,
the increase of GH dose is limited by the medication label
for SGA.
The addition of GnRH agonists has been tested in short
SGA adolescents in order to prolong GH treatment duration
and improve adult height outcome [27]. There is however no
convincing evidence that AH in short GH-treated SGA chil-
dren can be improved by postponing pubertal onset with
GnRH agonist. In a randomized study of short adolescents
(Tanner stage 2 and 3), born either with appropriate Birth
weight (n = 11) or SGA (n = 6) with a predicted adult height
below −2 SDS and receiving GH in combination with a
GnRH agonist for 3 years, no difference in adult height was
observed in comparison with an age- and height-matched
untreated control group (n = 15) [27]. Lem et al. [5] have
shown that adding a GnRH agonist for 2 years in short
GH-treated SGA children with a height at onset of puberty
<140 cm (considered as having a poor AH expectation) had
a similar AH than patients receiving GH only. Prolonging
the pubertal growth phase for a much longer period by
GnRH agonist and/or the addition of estrogen blocking
agents should be further explored, as GnRH agonist adminis-
tration for 3.5 years was found to increase adult height by 0.6
SDS in a group of 26 adolescents with very short stature of
different origins [28]. The psychosocial impact of such com-
bined treatment (school performance, social acceptance, and
general self-worth) should also be further investigated.
In conclusion, our study shows that short SGA adoles-
cents starting GH therapy at an early pubertal stage have a
modest and variable height gain. The best adult height
outcome can be expected in those with the lowest height
deficit at start of GH treatment. Our finding that female
patients and those with a higher body weight are at higher
risk for a poor adult height outcome needs confirmation
in larger studies.
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